Shall we properly re-examine the status of allogeneic lymphocyte therapy for recurrent early pregnancy failure?

American Journal of Reproductive Immunology

Volumn 51, Issue 1, 2004, Pages 7-15

  Clark, David A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Evidence based medicine; Immunotherapy; Implantation failure; Recurrent abortion

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; AUTOANTIBODY; HEPARIN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN;

ALLOGENEIC LYMPHOCYTE THERAPY; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFECT; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; IMMUNOTHERAPY; INFORMED CONSENT; METHODOLOGY; NONHUMAN; PATIENT SELECTION; PREGNANCY DISORDER; PRIORITY JOURNAL; RECURRENT ABORTION; REVIEW; SPONTANEOUS ABORTION;

ABORTION, HABITUAL; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; PREGNANCY; PREGNANCY MAINTENANCE; RANDOMIZED CONTROLLED TRIALS;

EID: 0442278336     PISSN: 87558920     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.8755-8920.2003.00133.x     Document Type: Review

References (50)

1. Chaouat G: Should we re-examine the status of lymphocyte alloimmunization therapy for recurrent spontaneous abortion? Am J Reprod Immunol 2003; 50:433-439.
2. The Recurrent Miscarriage Immunotherapy Trialists Group: Worldwide collaborative observational study and meta-analysis on allogeneic leukocyte immunotherapy for recurrent spontaneous abortion. Am J Reprod Immunol 1994; 32:55-72 and 257-280.
3. Daya S, Gunby J, the Recurrent Miscarriage Immunotherapy Trialists Group: The effectiveness of allogeneic leukocyte immunotherapy in unexplained primary recurrent spontaneous abortion. Am J Reprod Immunol 1994; 32:294-302.
4. Maclure M: Dr. Tom Chalmers 1917-1995: The trials of a randomizer. Can Med Assoc J 1996; 155:757-760.
5. Haynes RB, Sackett DL, Taylor DW, Gibson ES, Johnson AL: Increased absenteeism from work after detection and labeling of hypertensive patients. New Engl J Med 1978; 299:741-744.
6. Medawar PB: Advice to a Young Scientist. New York, Harper & Row, 1979.
7. Solzhenitzsyn AI: Cancer Ward. Harmondsworth, Penguin, 1971.
8. Vogelzang NJ, Raghavan D, Kennedy BJ: VP-16-213 (etoposide): The mandrake root from Issyk-Kul. Am J Med 1982; 72:136-144.
9. Hunter DJ: Evidence-based policy and practice: Riding for a fall? J Royal Soc Med 2003; 93:194-196.
10. Oxman AD, Clarke MJ, Stewart LA: From science to practice. Meta-analysis using individual patient data are needed. JAMA 1995; 274:830-836.
11. Daya S, Gunby J, Clark DA: Intravenous immunoglobulin therapy for recurrent spontaneous abortion: A meta-analysis. Am J Reprod Immunol 1998; 39:69-76.
12. Coulam CB, Stephenson M, Stern J, Clark DA: Immunotherapy for recurrent pregnancy loss: Analysis of results from clinical trials. Am J Reprod Immunol 1996; 35:352-359.
13. Clark DA, Daya S, Coulam CB, Gunby J, the Recurrent Immunotherapy Trialists Group: Implications of abnormal trophoblast karyotype from the evidence-based approach to the understanding, investigation, and treatment of recurrent spontaneous abortion. Am J Reprod Immunol 1996; 35:495-498.
14. Ho HN, Gill TJ, Hsieh HJ, Jiang JJ, Lee TY, Hsieh CY: Immunotherapy for recurrent spontaneous abortions in a Chinese population. Am J Reprod Immunol 1991; 25:10-15.
15. Clark DA, Coulam CB, Daya S, Chaouat G: Unexplained sporadic and recurrent miscarriage in the new millennium: A critical analysis of immune mechanisms and treatment. Human Reprod Update 2001; 7:501-511.
16. Clark DA, Banwatt D, Chaouat G: Stress-triggered abortion in mice is prevented by alloimmunization. Am J Reprod Immunol 1993; 29:141-147.
17. Arck PC: Stress and pregnancy loss: Role of mediators, hormones and neurotransmittors. Am J Reprod Immunol 2001; 46:117-123.
18. Clark DA, Daya S: Trials and tribulation in the treatment of recurrent spontaneous abortion. Am J Reprod Immunol 1991; 25:18-24.
19. Ober C, Karrison T, Odem RR, Barnes RB, Branch DW, Stephenson MD, Baron B, Walker MA, Scott JR, Schreiber JR: Mononuclear-cell immunization in prevention of recurrent miscarriages: A randomised trial. Lancet 1999; 354:365-369.
20. Gleicher N: Some thoughts on the reproductive autoimmune failure syndrome (RAFS) and Th-1 versus Th-2 immune response. Am J Reprod Immunol 2002; 48:252-254.
21. Kaider BD, Coulam CB, Roussev RG: Murine embyros as a direct target for some human autoantibodies in vitro. Hum Reprod 1999; 14:2556-2561.
22. Sackett DL, Hoey J: Why clinical trials fail but needn't: A new series is launched. Can Med Assoc J 2000; 162:1311-1314.
23. Clark D, Chaouat G: Immunomodulation by CD200 as a basis for prevention of cytokine-dependent fetal loss syndrome. Am J Reprod Immunol 2003; 49:350-351.
24. Clark DA, Manuel J, Gorczynski RM, Blajchman M: Labile CD200 tolerance signal important in transfusion-related immunomodulation (TRIM) prevention of recurrent miscarriages. Am J Reprod Immunol 2001; 45:361.
25. Mowbray JF, Underwood JL: Effect of paternal lymphocyte immunization on birthweight and pregnancy outcome. In Cellular and Molecular Biology of the Materno-Fetal Relationship, G Chaouat, JF Mowbray (eds). Paris, INSERM/John Libby Eurotext, 1991, Colloque 212:295-302.
26. Smith JB, Cowchock FS, Lata JA, Hankinson BT: The number of cells used for immunotherapy of repeated spontaneous abortions influences pregnancy outcome. J Reprod Immunol 1992; 22:217-224.
27. Stricker RB, Steinleitner A, Winger EE: Intravenous immunoglobulin (IVIG) therapy for immunological abortion. Clin Appl Immunol Rev 2002; 2:187-199.
28. Call DR, Remick DG: Low molecular weight heparin is associated with greater cytokine production in stimulated whole blood model. Shock 1998; 10: 192-197.
29. Christiansen OB, Pedersen B, Rosgaard A, Husth M: A randomized, double-blind placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: Evidence for a therapeutic effect in women with secondary recurrent miscarriage. Hum Reprod 2002; 17:809-816.
30. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of randomised trials. Lancet 1998; 352:930-942.
31. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, David K, Killip T, Passamani E, Norris R: Effect of coronary artery bypass graft surgery on survival: Overview of 10 year results from randomized trials of the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344:563-570.
32. Vamvakas EC, Blajchman MA (eds). Immunomodulatory Effects of Blood Transfusion. Bethesda, MD, AABB Press, 1999.
33. Hayden M, Pignone M, Phillips C, Mulrow C: Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Int Med 2002; 136:161-172.
34. Sutcliffe AG: IVF Children: The First Generation. New York, Parthenon, 2002.
35. Chaouat G, Ledee-Bataille N, Zourbas S, Ostojic S, Dubanchet S, Martal J, Frydman R: Cytokines, implantation and early abortion: Re-examining the Th1/Th2 paradigm leads to question the single pathway, single therapy concept. Am J Reprod Immunol 2003; 50:177-186.
36. Robertson SA, Sharkey DJ: The role of semen in induction of maternal immune tolerance to pregnancy. Sem Immunol 2001; 13:243-254.
37. Tremellen KP, Valbuena D, Landeras J, Ballesteros A, Martinez J, Mendoza S, Norman RJ, Robertson SA, Simon C: The effect of intercourse on pregnancy rates during assisted human reproduction. Hum Reprod 2000; 15:2653-2658.
38. Coulam CB, Stern JJ: Effects of seminal plasma on implantation rates. Early Pregnancy 1995; 1:33-36.
39. Sanford TR, De M, Wood GW: Expression of colony stimulatory factors and inflammatory cytokines in the uterus of CD1 mice during days 1-3 of pregnancy. J Reprod Fertil 1992; 94:213-220.
40. De M, Sanford TR, Wood GW: Expression of interleukin 1, interleukin 6, and tumor necrosis factor α in mouse uterus during the peri-implantation period of pregnancy. J Reprod Fertil 1993; 97:83-89.
41. Trebichavsky I, Nyklicek O: Cells adherent to IUDs produce tumor necrosis factor α. Contraception 1993; 47:205-214.
42. Taketani Y, Kuo TM, Mizuno M. Comparison of cytokine levels and embryo toxicity in peritoneal fluids in women with treated or untreated endometriosis. Am J Obstet Gynecol 1992; 167:265-270.
43. Clark DA: Is there any evidence for immunologically mediated or immunologically modifiable early pregnancy failure? J Assist Reprod Genet 2003; 20:63-72.
44. Kwak-Kim JY, Chung-Bang HS, Ng SC, Ntrivalas EI, Mangubat CP, Beaman KD, Beer AE, Gilman-Sachs A: Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF. Hum Reprod 2003; 18:767-773.
45. Stewart-Akers AM, Krasnow JS, Brekosky J, DeLoia JA: Endometrial leukocytes are altered numerically and functionally in women with implantation defects. Am J Reprod Immunol 1998; 39:1-11.
46. Coulam CB, Roussev RG: Increasing circulating T-cell activation markers are linked to subsequent implantation failure after transfer of in vitro fertilized embryos. Am J Reprod Immunol 2003; 50:340-345.
47. Coulam CB, Roussev RG: Correlation of NK cell activation and implantation markers with NK cytotoxicity among women experiencing immunologic implantation failure after in vitro fertilization and embryo transfer. J Assist Reprod Genet 2003; 20:58-62.
48. Clark DA, Yu G, Levy GA, Gorczynski RM: Procoagulants in fetus rejection: The role of the OX-2 (CD200) tolerance signal. Seminars Immunol 2001; 13:255-263.
49. Clark DA, Yu G, Arck PC, Levy GA, Gorczynski RM: MD-1 is a critical part of the mechanism causing Th1-cytokine-triggered murine fetal loss syndrome. Am J Reprod Immunol 2003; 49:297-307.
50. Geva E, Yaron Y, Lessing JB, Yovel I, Vardinon N, Burke M, Amit A: Circulating autoimmune antibodies may be responsible for implantation failure in in vitro fertilization. Fertil Steril 1994; 62:802-806.